[
  {
    "ts": "2025-12-21T15:57:51+00:00",
    "headline": "FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, while maintaining a Neutral rating on the shares. Earlier on December 4, Bristol-Myers Squibb announced that the US FDA approved Breyanzi (lisocabtagene […]",
    "url": "https://finance.yahoo.com/news/fda-approves-bristol-myers-squibb-155751905.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "54ab56f3-a205-3276-bc73-1c68b90dd643",
      "content": {
        "id": "54ab56f3-a205-3276-bc73-1c68b90dd643",
        "contentType": "STORY",
        "title": "FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the best stocks to buy for the next 5 years. On December 15, Goldman Sachs raised the firm’s price target on Bristol-Myers Squibb to $57 from $51, while maintaining a Neutral rating on the shares. Earlier on December 4, Bristol-Myers Squibb announced that the US FDA approved Breyanzi (lisocabtagene […]",
        "pubDate": "2025-12-21T15:57:51Z",
        "displayTime": "2025-12-21T15:57:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "FDA Approves Bristol-Myers Squibb's Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-bristol-myers-squibb-155751905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-bristol-myers-squibb-155751905.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-21T15:44:58+00:00",
    "headline": "BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 15, BofA upgraded the company’s stock to “Buy” from “Neutral” with a price objective of $61, an increase from $52, given the company’s R&D pipeline, as reported by The Fly. As per the firm, 4-6 programs are expected […]",
    "url": "https://finance.yahoo.com/news/bofa-upgrades-bristol-myers-squibb-154458718.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9182f169-0a21-3cd3-9adc-65fecd6efad9",
      "content": {
        "id": "9182f169-0a21-3cd3-9adc-65fecd6efad9",
        "contentType": "STORY",
        "title": "BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 15, BofA upgraded the company’s stock to “Buy” from “Neutral” with a price objective of $61, an increase from $52, given the company’s R&D pipeline, as reported by The Fly. As per the firm, 4-6 programs are expected […]",
        "pubDate": "2025-12-21T15:44:58Z",
        "displayTime": "2025-12-21T15:44:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w_.mq2hxLlg_y2nUTx72ng--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6o8Kx8kFVS_oEolQVNGNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-upgrades-bristol-myers-squibb-154458718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-upgrades-bristol-myers-squibb-154458718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-21T15:55:00+00:00",
    "headline": "Cytokinetics set to battle Bristol Myers as FDA approves heart drug",
    "summary": "The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.",
    "url": "https://www.biopharmadive.com/news/cytokinetics-myqorzo-fda-approval-obstructive-hypertrophic-cardiomyopathy-camzyos/808456/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "50419927-b6c3-3e40-b8e5-e06fa77a8fb7",
      "content": {
        "id": "50419927-b6c3-3e40-b8e5-e06fa77a8fb7",
        "contentType": "STORY",
        "title": "Cytokinetics set to battle Bristol Myers as FDA approves heart drug",
        "description": "",
        "summary": "The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which is on its way to topping $1 billion in sales this year.",
        "pubDate": "2025-12-21T15:55:00Z",
        "displayTime": "2025-12-21T15:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/785a9e5dc53698e6739d0e4913d22f22",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSlSoVnbNlmgXsllTJugmA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/785a9e5dc53698e6739d0e4913d22f22.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZPxZRQ1ipIR.ob55oDUsdw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/785a9e5dc53698e6739d0e4913d22f22.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/cytokinetics-myqorzo-fda-approval-obstructive-hypertrophic-cardiomyopathy-camzyos/808456/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cytokinetics-set-battle-bristol-myers-155500463.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]